Department of Dermatology, Université De Paris, Hôpital Saint-Louis, Paris, France.
Expert Opin Emerg Drugs. 2021 Mar;26(1):17-26. doi: 10.1080/14728214.2021.1873949. Epub 2021 Jan 24.
: Basal cell carcinoma (BCC) is the most frequent skin malignancy, with incidence increasing worldwide. Most BCC can be cured with local treatments (surgery or topical therapies), but advanced or recurrent forms require specific therapies. Significant developments targeting the sonic hedgehog signalization pathway have been made in the past years, paving the way for new therapies.: This review details emerging drugs for BCC treatment, focusing on topical, intra-tumoral, and systemic therapies, such as new targeted therapies and immune checkpoint inhibitors. A literature search was conducted to identify ongoing studies using PudMed database and clinicaltrials.gov website.: Although surgery is and will probably remain the gold-standard therapy for BCC, treatment of recurrent, advanced, and metastatic tumors is evolving. Emergence of tumors resistant to targeted therapies lead the way to new approaches. Topical and intra-tumoral treatments represent alternatives to surgical morbidity, and many studies are ongoing. The first results of immune checkpoint inhibitors are encouraging in advanced and metastatic forms of the disease. New targeted therapies are needed to overcome or prevent the resistance to standard hedgehog pathway inhibitors.
基底细胞癌（BCC）是最常见的皮肤恶性肿瘤，其发病率在全球范围内呈上升趋势。大多数 BCC 可以通过局部治疗（手术或局部治疗）治愈，但晚期或复发性形式需要特定的治疗方法。在过去的几年中，针对 sonic hedgehog 信号通路的重要进展为新的治疗方法铺平了道路。
本文详细介绍了用于治疗 BCC 的新兴药物，重点介绍了局部、瘤内和全身治疗，如新型靶向治疗和免疫检查点抑制剂。使用 PubMed 数据库和 clinicaltrials.gov 网站进行了文献检索，以确定正在进行的研究。
虽然手术是并且可能仍然是 BCC 的金标准治疗方法，但复发性、晚期和转移性肿瘤的治疗正在不断发展。靶向治疗耐药肿瘤的出现为新方法开辟了道路。局部和瘤内治疗是手术发病率的替代方法，许多研究正在进行中。免疫检查点抑制剂在晚期和转移性疾病中的初步结果令人鼓舞。需要新的靶向治疗方法来克服或预防对标准 hedgehog 通路抑制剂的耐药性。
